JasSeah personal page - To The Moon

JasSeah

No personal profile

4Follow

3Followers

0Topic

0Badge

2021-06-30

Nice

Better Buy: Virgin Galactic vs. Lockheed Martin

2021-06-30

Yumz

Amazon Is Still The Undisputed King Of Cloud

2021-06-28

Woah

How Facebook Is Quietly Preparing to Dominate Virtual Reality

2021-06-25

Cool

Why Apple's Stock Valuation Could Present Long-Term Buying Opportunity

2021-06-23

Cool

Second Sight Medical Products Announces Pricing of Public Offering

2021-06-21

Great

Biden's top tax rate on capital gains, dividends would be among highest in developed world

2021-06-21

Nice

New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End

2021-06-19

Shiok

New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3580457839820972","uuid":"3580457839820972","gmtCreate":1617364712684,"gmtModify":1617364712684,"name":"JasSeah","pinyin":"jasseah","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":4,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":151194802,"gmtCreate":1625066527106,"gmtModify":1703735400249,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/151194802","repostId":"2147169298","repostType":4,"repost":{"id":"2147169298","pubTimestamp":1625064508,"share":"https://ttm.financial/m/news/2147169298?lang=&edition=fundamental","pubTime":"2021-06-30 22:48","market":"us","language":"en","title":"Better Buy: Virgin Galactic vs. Lockheed Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2147169298","media":"Motley Fool","summary":"These two businesses are in the same industry but couldn't be more different.","content":"<p>The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"space race,\" launching test rockets and satellites for businesses and the U.S. government. But there are plenty of other companies in this private space race. One is <b>Virgin Galactic</b> (NYSE:SPCE), which was started by Richard Branson in 2004 and went public through a special purpose acquisition company (SPAC) in 2019. Another is <b>Lockheed Martin</b> (NYSE:LMT), the world's largest defense contractor.</p>\n<p>Which is a better buy: Virgin Galactic or Lockheed Martin? Let's take a look.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5f0851439294a2ef253f90479b7d5b2\" tg-width=\"700\" tg-height=\"491\"><span>Image source: Getty Images.</span></p>\n<h2>Virgin Galactic</h2>\n<p>Virgin Galactic is trying to build a modern aerospace company with a focus on consumer trips. Its goal is to develop \"a new generation of space vehicles to open space for everyone,\" according to its website. It has manufactured and will continue to manufacture different spaceships, with a goal of targeting researchers and wealthy private individuals for sub-orbital flights. Each ticket costs $250 thousand, and the company has a total of&nbsp; approximately 600 Future Astronauts (what it calls customers who have booked future flights) at the end of the first quarter.</p>\n<p>One thing investors should note with Virgin Galactic is that it doesn't actually have a business yet. In Q1 it brought in $0 of revenue (yes, that number is correct), burned $50 million, and has a little over $600 million in cash on its balance sheet. That cash pile gives it a good cushion, at least for a few quarters, but it is likely that the company will need to raise more money in the coming years.</p>\n<p>It has typically done that by issuing stock. Since going public in 2019, its shares outstanding have gone up 179%. Virgin Galactic currently has a market cap of $12.8 billion. Since it doesn't have a business right now, there's not much to reference this market cap to, but it implies that investors should expect the company to do at least a few billion in sales and hundreds of millions in profits at some point.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ab1895d73d79c678e757ad436915a12\" tg-width=\"720\" tg-height=\"433\"><span>Data by YCharts.</span></p>\n<h2>Lockheed Martin</h2>\n<p>Lockheed Martin is an American defense, aerospace, security, and technology company that has been doing business for the U.S. government for decades. Its largest business comes from aeronautics (which includes things like fighter jets), but it also has large missile, mission systems, and space-business lines as well. In fact, Lockheed Martin was the company that designed a helicopter for NASA that could fly on Mars.</p>\n<p>The conglomerate is guiding for around $68 billion in sales and $8.9 billion in cash generated from operations this year. With a market cap of $106 billion, the stock has a forward price-to-operating-cash-flow (P/OCF) of 11.9. Lockheed also returns tons of cash to shareholders through dividends and share repurchases. Its dividend yield is 2.72%, and its share count has come down each of the last five years.</p>\n<h2>So which is the better buy?</h2>\n<p>After comparing these two stocks, I think it is clear which is better to own: Lockheed Martin. Virgin Galactic does not have an actual business right now, is hemorrhaging cash, and has seen its share count go up 179% in less than two years. At this time, buying shares in Virgin Galactic is not investing but speculating.</p>\n<p>Lockheed Martin, on the other hand, has a diversified business and the most reliable customer in the world (the U.S. government). Plus, it consistently returns cash to shareholders through dividends and share repurchases. It might not have the hype of Virgin Galactic, whose shares seem to go up or down 10% a day, but Lockheed Martin is the better buy for long-term investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: Virgin Galactic vs. Lockheed Martin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: Virgin Galactic vs. Lockheed Martin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMT":"洛克希德马丁","SPCE":"维珍银河"},"source_url":"https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147169298","content_text":"The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"space race,\" launching test rockets and satellites for businesses and the U.S. government. But there are plenty of other companies in this private space race. One is Virgin Galactic (NYSE:SPCE), which was started by Richard Branson in 2004 and went public through a special purpose acquisition company (SPAC) in 2019. Another is Lockheed Martin (NYSE:LMT), the world's largest defense contractor.\nWhich is a better buy: Virgin Galactic or Lockheed Martin? Let's take a look.\nImage source: Getty Images.\nVirgin Galactic\nVirgin Galactic is trying to build a modern aerospace company with a focus on consumer trips. Its goal is to develop \"a new generation of space vehicles to open space for everyone,\" according to its website. It has manufactured and will continue to manufacture different spaceships, with a goal of targeting researchers and wealthy private individuals for sub-orbital flights. Each ticket costs $250 thousand, and the company has a total of  approximately 600 Future Astronauts (what it calls customers who have booked future flights) at the end of the first quarter.\nOne thing investors should note with Virgin Galactic is that it doesn't actually have a business yet. In Q1 it brought in $0 of revenue (yes, that number is correct), burned $50 million, and has a little over $600 million in cash on its balance sheet. That cash pile gives it a good cushion, at least for a few quarters, but it is likely that the company will need to raise more money in the coming years.\nIt has typically done that by issuing stock. Since going public in 2019, its shares outstanding have gone up 179%. Virgin Galactic currently has a market cap of $12.8 billion. Since it doesn't have a business right now, there's not much to reference this market cap to, but it implies that investors should expect the company to do at least a few billion in sales and hundreds of millions in profits at some point.\nData by YCharts.\nLockheed Martin\nLockheed Martin is an American defense, aerospace, security, and technology company that has been doing business for the U.S. government for decades. Its largest business comes from aeronautics (which includes things like fighter jets), but it also has large missile, mission systems, and space-business lines as well. In fact, Lockheed Martin was the company that designed a helicopter for NASA that could fly on Mars.\nThe conglomerate is guiding for around $68 billion in sales and $8.9 billion in cash generated from operations this year. With a market cap of $106 billion, the stock has a forward price-to-operating-cash-flow (P/OCF) of 11.9. Lockheed also returns tons of cash to shareholders through dividends and share repurchases. Its dividend yield is 2.72%, and its share count has come down each of the last five years.\nSo which is the better buy?\nAfter comparing these two stocks, I think it is clear which is better to own: Lockheed Martin. Virgin Galactic does not have an actual business right now, is hemorrhaging cash, and has seen its share count go up 179% in less than two years. At this time, buying shares in Virgin Galactic is not investing but speculating.\nLockheed Martin, on the other hand, has a diversified business and the most reliable customer in the world (the U.S. government). Plus, it consistently returns cash to shareholders through dividends and share repurchases. It might not have the hype of Virgin Galactic, whose shares seem to go up or down 10% a day, but Lockheed Martin is the better buy for long-term investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151195446,"gmtCreate":1625066508485,"gmtModify":1703735399257,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Yumz","listText":"Yumz","text":"Yumz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151195446","repostId":"1168354842","repostType":4,"repost":{"id":"1168354842","pubTimestamp":1625064927,"share":"https://ttm.financial/m/news/1168354842?lang=&edition=fundamental","pubTime":"2021-06-30 22:55","market":"us","language":"en","title":"Amazon Is Still The Undisputed King Of Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=1168354842","media":"TheStreet","summary":"Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains t","content":"<p>Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.</p>\n<p>Last year was outstanding for cloud infrastructure, as the industry generated over $60 billion in revenues globally. At least this is what Gartner’s most recently issuedreportsuggests. IaaS sales grew a whopping 41% over 2019, driven by an acceleration in cloud adoption.</p>\n<p>One of the great beneficiaries of the cloud trends has been Amazon. The company, through its Amazon Web Services division, produced over 40% of the total industry revenues, reinforcing its status as the undisputed king of cloud infrastructure in the world.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a2c7a47d64871690408cff1b60106bca\" tg-width=\"1200\" tg-height=\"899\"><span>Figure 1: Amazon Web Serviced (AWS).</span></p>\n<p><b>A look at the numbers</b></p>\n<p>The table below summarizes Gartner’s findings about cloud IaaS. Amazon’s revenues, at $26.2 billion, were more than double Microsoft’s, the number two player in the space. All other competitors combined, Microsoft aside, produced less in IaaS revenues than Amazon.</p>\n<p>The worse news for Amazon is that its market share has declined noticeably since 2019. The company used to control nearly 45% of the industry but lost roughly four percentage points in 12 months. It looks like each of the next four competitors nibbled away at Amazon’s dominance in 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/65fc2aae6052c89cc17d34000360050d\" tg-width=\"825\" tg-height=\"513\"><span>Figure 2: Worldwide IaaS public market cloud services market share, 2019-2020.</span></p>\n<p>Worth noting, the table above addresses cloud infrastructure only, which I estimate to represent at least 60% of Amazon Web Services revenues. Not listed are cloud platform (PaaS) and packaged software (SaaS) – the latter of which Amazon is not a large player in.</p>\n<p><b>Why cloud matters</b></p>\n<p>Cloud adoption is one of those secular trends of the past decade – along with the internet in the 1990s, big data and connected devices in the 2000s – that has reached escape velocity. Gartner has offered the following quote that supports the idea:</p>\n<blockquote>\n “The era of CIOs investing in cloud IaaS and PaaS discretely is long over. Cloud market will continue to grow, [and] the real opportunity for providers comes from growth in cloud-adjacent technology markets such as edge, 5G and AI.”\n</blockquote>\n<p>For the revenue growth opportunities alone, cloud is an important factor in Amazon’s success. But what some may still not know is that AWS, representing only 12% of Amazon’s revenues in 2020, accounted for nearly 60% of the company’s operating profits. And probably even more so than e-commerce, Amazon’s cloud business is likely to see margins expand with gains of scale.</p>\n<p>Therefore, for as long as the table above continues to look good, the Seattle-based cloud giant will likely see profits and cash flow rise – and Amazon stock should benefit.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Is Still The Undisputed King Of Cloud</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Is Still The Undisputed King Of Cloud\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.\nLast year was...</p>\n\n<a href=\"https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168354842","content_text":"Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.\nLast year was outstanding for cloud infrastructure, as the industry generated over $60 billion in revenues globally. At least this is what Gartner’s most recently issuedreportsuggests. IaaS sales grew a whopping 41% over 2019, driven by an acceleration in cloud adoption.\nOne of the great beneficiaries of the cloud trends has been Amazon. The company, through its Amazon Web Services division, produced over 40% of the total industry revenues, reinforcing its status as the undisputed king of cloud infrastructure in the world.\nFigure 1: Amazon Web Serviced (AWS).\nA look at the numbers\nThe table below summarizes Gartner’s findings about cloud IaaS. Amazon’s revenues, at $26.2 billion, were more than double Microsoft’s, the number two player in the space. All other competitors combined, Microsoft aside, produced less in IaaS revenues than Amazon.\nThe worse news for Amazon is that its market share has declined noticeably since 2019. The company used to control nearly 45% of the industry but lost roughly four percentage points in 12 months. It looks like each of the next four competitors nibbled away at Amazon’s dominance in 2020.\nFigure 2: Worldwide IaaS public market cloud services market share, 2019-2020.\nWorth noting, the table above addresses cloud infrastructure only, which I estimate to represent at least 60% of Amazon Web Services revenues. Not listed are cloud platform (PaaS) and packaged software (SaaS) – the latter of which Amazon is not a large player in.\nWhy cloud matters\nCloud adoption is one of those secular trends of the past decade – along with the internet in the 1990s, big data and connected devices in the 2000s – that has reached escape velocity. Gartner has offered the following quote that supports the idea:\n\n “The era of CIOs investing in cloud IaaS and PaaS discretely is long over. Cloud market will continue to grow, [and] the real opportunity for providers comes from growth in cloud-adjacent technology markets such as edge, 5G and AI.”\n\nFor the revenue growth opportunities alone, cloud is an important factor in Amazon’s success. But what some may still not know is that AWS, representing only 12% of Amazon’s revenues in 2020, accounted for nearly 60% of the company’s operating profits. And probably even more so than e-commerce, Amazon’s cloud business is likely to see margins expand with gains of scale.\nTherefore, for as long as the table above continues to look good, the Seattle-based cloud giant will likely see profits and cash flow rise – and Amazon stock should benefit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150921896,"gmtCreate":1624883633715,"gmtModify":1703846939524,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150921896","repostId":"2146339002","repostType":4,"repost":{"id":"2146339002","pubTimestamp":1624880751,"share":"https://ttm.financial/m/news/2146339002?lang=&edition=fundamental","pubTime":"2021-06-28 19:45","market":"us","language":"en","title":"How Facebook Is Quietly Preparing to Dominate Virtual Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2146339002","media":"Motley Fool","summary":"VR gaming accounts for less than 1% of the gaming market, but Facebook is going all in. What does Zuckerberg know that we don't?","content":"<p>According to The Verge, nearly 20% of <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b>'s (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios for years, most recently BigBox VR (creator of <i>Population: One</i>, the <i>Fortnite</i> of VR) and Unit 2 Games (creator of Craya, a <b>Roblox</b>-esque VR gaming platform), for undisclosed sums.</p>\n<p>These continuous investments in talent and studio acquisitions may seem steep for a business segment that accounts for less than 3% of Facebook's top line. But Mark Zuckerberg's ambitious vision for VR is powering a shopping spree that likely won't stop anytime soon. Is Facebook ahead of the game, or will its Oculus VR venture fail to move the needle?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f686cdff7303434853836ea6ee34a8f6\" tg-width=\"700\" tg-height=\"438\"><span>Image source: Getty Images.</span></p>\n<h2>The future of VR gaming</h2>\n<p>Zuckerberg has been talking up VR more than usual lately, partly thanks to accelerated adoption of the Oculus Quest 2 VR headset (according to Facebook -- but the company does not explicitly report figures for sold VR hardware). The CEO's first major talking point in Facebook's latest earnings report was VR and AR, predicting \"augmented and virtual reality to unlock a massive amount of value, both in people's lives and the economy overall.\"</p>\n<p>His excitement about the technology is not unwarranted -- Fortune Business Insights forecasts that the global market for VR gaming will reach $45.2 billion by 2027 (from $5.1 billion in 2019). This translates to a compounded annual growth rate (CAGR) of 31.8%, compared to a CAGR of only 5.3% for the overall gaming console market over the same forecast period.</p>\n<h2>How Facebook got ahead</h2>\n<p>Facebook's strategy for VR gaming domination starts with laying a solid foundation of technology and developer talent. In classic Facebook fashion, its primary tactic has been acquiring existing VR hardware and software companies.</p>\n<p>Since acquiring Oculus VR for $2 billion in 2014, the company has made significant progress in improving its VR hardware to better suit customers' needs. The current Oculus Quest 2 is a stand-alone headset (i.e., no wires to trip on or tangle up while playing) and requires no external device (such as a console or PC). Conversely, <b>Sony</b>'s (NYSE:SONY) wired PlayStation VR headset requires a PlayStation console. The Quest 2's wireless, low-hardware conveniences combined with its lower price point relative to any other major headset on the market give Facebook a competitive edge when it comes to hardware.</p>\n<p>But even the best VR headset is useless without great games, making Facebook's VR studio acquisitions crucial to building up its VR ecosystem. By acquiring small yet high-performing studios, Facebook is securing revenue from already-popular VR games on Oculus and retaining top software developers to create exclusive content within the Oculus platform. Considering the company's standard four-year stock option vesting schedule, it's unlikely that developers from studios like BigBox or Unit 2 will jump ship to work for a competitor anytime soon.</p>\n<h2>Why it'll stay ahead</h2>\n<p>If you know Facebook's business model, you're probably wondering when ads come into play. The company has announced that it will begin testing ads in select games on the Oculus platform, but it's still up in the air what exactly the ad experience will look like once testing begins -- and how VR gamers will react.</p>\n<p>If the company can manage to integrate ads without breaking the immersive gaming experience, it will help developers earn more revenue (thus, attracting more developers to the Oculus platform) and could even make games more realistic. For example, real ads appearing on in-game TV screens and billboards would not break players' immersion in their gaming world, while still driving revenue for developers and Facebook.</p>\n<p>Beyond attracting developers for top-tier content, Facebook has a unique edge in attracting consumers as well -- its massive social networking user base. No other VR headset can offer such easy accessibility (low price point with no required console purchase) and such a high potential for network effects.</p>\n<p>For example, it would be much easier for a friend to influence you to purchase a $300 all-in-<a href=\"https://laohu8.com/S/AONE\">one</a> VR headset than a PlayStation console <i>and</i> headset, which would total more than twice the cost of the Quest 2. Don't get me wrong -- Sony is a leading competitor in the VR gaming space and has shipped the most VR hardware units to date, but the company's network effects are arguably limited to existing PlayStation owners (about 15.7 million monthly active users, between the PS4 and the PS5).</p>\n<p>Facebook's 2.8 billion monthly active users have much more potential to add value to the Oculus platform by sheer volume of players, especially when it comes to popular social VR games like <i>Population: One</i>, <i>Craya</i>, and <i>Beat Saber Multiplayer</i> (developed by yet another Facebook-acquired studio, Beat Games). Social gaming experiences are inherently more valuable with more players.</p>\n<p>While some VR multiplayer games are cross-platform (i.e., an Oculus player can game with a PS VR player), Facebook will likely tighten up its exclusive content offerings to attract and retain players. As long as the company rolls out ad content in a way that feels relatively organic to Oculus players, Facebook is set up for success in rapidly gaining market share in VR gaming.</p>\n<h2>What to watch for</h2>\n<p>While Facebook's VR gaming revenue isn't reported explicitly (yet), the company's \"other revenue\" business segment is primarily Oculus. In Facebook's first-quarter 2021 earnings report, this segment grew 146% year over year to $732 million, implying an impressive growth rate for the company's VR business. Further, the Quest 2 has become the most used VR headset on popular gaming platform Steam, and by many estimates the Quest 2 is selling at least twice as fast as PlayStation VR, despite lagging behind in current overall market share.</p>\n<p>Keep an eye on this \"other revenue\" segment in future earnings reports, as well as any hard figures reported by the company on VR gaming revenue. More cautious investors may also want to wait for Facebook to complete its in-game ad testing process before investing based on the company's growth potential in VR. It is undoubtedly a risk to user growth if ad content is not executed smoothly.</p>\n<p>It's impossible to dive into every point in Facebook's value and growth story in <a href=\"https://laohu8.com/S/AONE.U\">one</a> sitting, but the stock seems fairly valued given its growth potential -- FB is even rated \"undervalued\" by Morningstar. The company's wide economic moat in social gaming is unmatched thanks to a massive user base and vast user data, and these competitive advantages can easily translate to driving profits and market share for its VR gaming business.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Facebook Is Quietly Preparing to Dominate Virtual Reality</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Facebook Is Quietly Preparing to Dominate Virtual Reality\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to The Verge, nearly 20% of Facebook's (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146339002","content_text":"According to The Verge, nearly 20% of Facebook's (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios for years, most recently BigBox VR (creator of Population: One, the Fortnite of VR) and Unit 2 Games (creator of Craya, a Roblox-esque VR gaming platform), for undisclosed sums.\nThese continuous investments in talent and studio acquisitions may seem steep for a business segment that accounts for less than 3% of Facebook's top line. But Mark Zuckerberg's ambitious vision for VR is powering a shopping spree that likely won't stop anytime soon. Is Facebook ahead of the game, or will its Oculus VR venture fail to move the needle?\nImage source: Getty Images.\nThe future of VR gaming\nZuckerberg has been talking up VR more than usual lately, partly thanks to accelerated adoption of the Oculus Quest 2 VR headset (according to Facebook -- but the company does not explicitly report figures for sold VR hardware). The CEO's first major talking point in Facebook's latest earnings report was VR and AR, predicting \"augmented and virtual reality to unlock a massive amount of value, both in people's lives and the economy overall.\"\nHis excitement about the technology is not unwarranted -- Fortune Business Insights forecasts that the global market for VR gaming will reach $45.2 billion by 2027 (from $5.1 billion in 2019). This translates to a compounded annual growth rate (CAGR) of 31.8%, compared to a CAGR of only 5.3% for the overall gaming console market over the same forecast period.\nHow Facebook got ahead\nFacebook's strategy for VR gaming domination starts with laying a solid foundation of technology and developer talent. In classic Facebook fashion, its primary tactic has been acquiring existing VR hardware and software companies.\nSince acquiring Oculus VR for $2 billion in 2014, the company has made significant progress in improving its VR hardware to better suit customers' needs. The current Oculus Quest 2 is a stand-alone headset (i.e., no wires to trip on or tangle up while playing) and requires no external device (such as a console or PC). Conversely, Sony's (NYSE:SONY) wired PlayStation VR headset requires a PlayStation console. The Quest 2's wireless, low-hardware conveniences combined with its lower price point relative to any other major headset on the market give Facebook a competitive edge when it comes to hardware.\nBut even the best VR headset is useless without great games, making Facebook's VR studio acquisitions crucial to building up its VR ecosystem. By acquiring small yet high-performing studios, Facebook is securing revenue from already-popular VR games on Oculus and retaining top software developers to create exclusive content within the Oculus platform. Considering the company's standard four-year stock option vesting schedule, it's unlikely that developers from studios like BigBox or Unit 2 will jump ship to work for a competitor anytime soon.\nWhy it'll stay ahead\nIf you know Facebook's business model, you're probably wondering when ads come into play. The company has announced that it will begin testing ads in select games on the Oculus platform, but it's still up in the air what exactly the ad experience will look like once testing begins -- and how VR gamers will react.\nIf the company can manage to integrate ads without breaking the immersive gaming experience, it will help developers earn more revenue (thus, attracting more developers to the Oculus platform) and could even make games more realistic. For example, real ads appearing on in-game TV screens and billboards would not break players' immersion in their gaming world, while still driving revenue for developers and Facebook.\nBeyond attracting developers for top-tier content, Facebook has a unique edge in attracting consumers as well -- its massive social networking user base. No other VR headset can offer such easy accessibility (low price point with no required console purchase) and such a high potential for network effects.\nFor example, it would be much easier for a friend to influence you to purchase a $300 all-in-one VR headset than a PlayStation console and headset, which would total more than twice the cost of the Quest 2. Don't get me wrong -- Sony is a leading competitor in the VR gaming space and has shipped the most VR hardware units to date, but the company's network effects are arguably limited to existing PlayStation owners (about 15.7 million monthly active users, between the PS4 and the PS5).\nFacebook's 2.8 billion monthly active users have much more potential to add value to the Oculus platform by sheer volume of players, especially when it comes to popular social VR games like Population: One, Craya, and Beat Saber Multiplayer (developed by yet another Facebook-acquired studio, Beat Games). Social gaming experiences are inherently more valuable with more players.\nWhile some VR multiplayer games are cross-platform (i.e., an Oculus player can game with a PS VR player), Facebook will likely tighten up its exclusive content offerings to attract and retain players. As long as the company rolls out ad content in a way that feels relatively organic to Oculus players, Facebook is set up for success in rapidly gaining market share in VR gaming.\nWhat to watch for\nWhile Facebook's VR gaming revenue isn't reported explicitly (yet), the company's \"other revenue\" business segment is primarily Oculus. In Facebook's first-quarter 2021 earnings report, this segment grew 146% year over year to $732 million, implying an impressive growth rate for the company's VR business. Further, the Quest 2 has become the most used VR headset on popular gaming platform Steam, and by many estimates the Quest 2 is selling at least twice as fast as PlayStation VR, despite lagging behind in current overall market share.\nKeep an eye on this \"other revenue\" segment in future earnings reports, as well as any hard figures reported by the company on VR gaming revenue. More cautious investors may also want to wait for Facebook to complete its in-game ad testing process before investing based on the company's growth potential in VR. It is undoubtedly a risk to user growth if ad content is not executed smoothly.\nIt's impossible to dive into every point in Facebook's value and growth story in one sitting, but the stock seems fairly valued given its growth potential -- FB is even rated \"undervalued\" by Morningstar. The company's wide economic moat in social gaming is unmatched thanks to a massive user base and vast user data, and these competitive advantages can easily translate to driving profits and market share for its VR gaming business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122334934,"gmtCreate":1624596846728,"gmtModify":1703841363133,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/122334934","repostId":"1136202921","repostType":4,"repost":{"id":"1136202921","pubTimestamp":1624591759,"share":"https://ttm.financial/m/news/1136202921?lang=&edition=fundamental","pubTime":"2021-06-25 11:29","market":"us","language":"en","title":"Why Apple's Stock Valuation Could Present Long-Term Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1136202921","media":"Benzinga","summary":"Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan St","content":"<p><b>Apple Inc.</b>(NASDAQ:AAPL) shares have shown&nbsp;muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.</p>\n<p><b>The Apple Analyst:</b>Katy Huberty reiterated an Overweight rating on Apple with a $162 price target.</p>\n<p><b>The Apple Takeaways:</b>The incoming call volume on Apple shares is at a low amid investor concerns over a seasonally low&nbsp;period in the iPhone cycle,regulatory risk&nbsp;and difficult comps relative to the COVID-19-driven work-from-home&nbsp;and study-from-home&nbsp;demand, Huberty said in a note.</p>\n<p>Additionally, investors fear&nbsp;a more evolutionary iPhone s-cycle will lead to extended&nbsp;iPhone replacement cycles, the analyst said.</p>\n<p>Revenues will likely decline in 2022, increasing the likelihood of negative estimate revisions, she said.</p>\n<p>\"We recognize these risks but have a more positive outlook,\" Huberty said.</p>\n<p>The dominant bear case narrative now is the iPhone entering a more modest upgrade or \"s\" cycle —&nbsp;a period when iPhone revenue historically declined at a double-digit rate, the analyst said. She forecast a low risk of similar iPhone revenue decline next year.</p>\n<p>This is due to the longer period of iPhone replacement cycle relative to the past, an expansion to Apple's trade-in, financing and installment offers and 5G adoption, which is still in its nascent stage, Huberty said.</p>\n<p>\"Taken together, these factors build confidence that the iPhone 13 cycle will not look like past s-cycles, which is reflected in our updated FY22 iPhone forecast of 231M units,\" the analyst said.</p>\n<p>The June quarter&nbsp;will be stronger than originally expected, as iPhone and iPad builds are tracking ahead of Morgan Stanley's estimate, she said.</p>\n<p>Huberty&nbsp;raised her June quarter revenue and EPS estimates by 3%-5%.</p>\n<p>Apple's catalyst path is more back-end loaded this year, the analyst said.</p>\n<p>The company can drive low-teens annual revenue growth and high-teens annual EPS growth between fiscal years 2020 and 2023, she said.</p>\n<p>\"At24xFV/FCF, we believe the current valuation presents a good long-term buying opportunity.\"</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple's Stock Valuation Could Present Long-Term Buying Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple's Stock Valuation Could Present Long-Term Buying Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.\nThe Apple Analyst:Katy ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136202921","content_text":"Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.\nThe Apple Analyst:Katy Huberty reiterated an Overweight rating on Apple with a $162 price target.\nThe Apple Takeaways:The incoming call volume on Apple shares is at a low amid investor concerns over a seasonally low period in the iPhone cycle,regulatory risk and difficult comps relative to the COVID-19-driven work-from-home and study-from-home demand, Huberty said in a note.\nAdditionally, investors fear a more evolutionary iPhone s-cycle will lead to extended iPhone replacement cycles, the analyst said.\nRevenues will likely decline in 2022, increasing the likelihood of negative estimate revisions, she said.\n\"We recognize these risks but have a more positive outlook,\" Huberty said.\nThe dominant bear case narrative now is the iPhone entering a more modest upgrade or \"s\" cycle — a period when iPhone revenue historically declined at a double-digit rate, the analyst said. She forecast a low risk of similar iPhone revenue decline next year.\nThis is due to the longer period of iPhone replacement cycle relative to the past, an expansion to Apple's trade-in, financing and installment offers and 5G adoption, which is still in its nascent stage, Huberty said.\n\"Taken together, these factors build confidence that the iPhone 13 cycle will not look like past s-cycles, which is reflected in our updated FY22 iPhone forecast of 231M units,\" the analyst said.\nThe June quarter will be stronger than originally expected, as iPhone and iPad builds are tracking ahead of Morgan Stanley's estimate, she said.\nHuberty raised her June quarter revenue and EPS estimates by 3%-5%.\nApple's catalyst path is more back-end loaded this year, the analyst said.\nThe company can drive low-teens annual revenue growth and high-teens annual EPS growth between fiscal years 2020 and 2023, she said.\n\"At24xFV/FCF, we believe the current valuation presents a good long-term buying opportunity.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123888429,"gmtCreate":1624415778261,"gmtModify":1703836005089,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123888429","repostId":"2145061761","repostType":4,"repost":{"id":"2145061761","pubTimestamp":1624411200,"share":"https://ttm.financial/m/news/2145061761?lang=&edition=fundamental","pubTime":"2021-06-23 09:20","market":"us","language":"en","title":"Second Sight Medical Products Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145061761","media":"Business Wire","summary":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Se","content":"<p><b>LOS ANGELES, June 23, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EYES\">Second Sight Medical Products</a>, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.</p>\n<p>The offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.</p>\n<p>ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.</p>\n<p>The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.</p>\n<p>The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About the Orion Visual Cortical Prosthesis System</b></p>\n<p>Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.</p>\n<p><b>About Second Sight Medical Products, Inc.</b></p>\n<p>Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Second Sight Medical Products Announces Pricing of Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSecond Sight Medical Products Announces Pricing of Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145061761","content_text":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.\nThe offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.\nThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\nThe securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout the Orion Visual Cortical Prosthesis System\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120083660,"gmtCreate":1624288187950,"gmtModify":1703832621820,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/120083660","repostId":"1194003246","repostType":4,"repost":{"id":"1194003246","pubTimestamp":1624281440,"share":"https://ttm.financial/m/news/1194003246?lang=&edition=fundamental","pubTime":"2021-06-21 21:17","market":"us","language":"en","title":"Biden's top tax rate on capital gains, dividends would be among highest in developed world","url":"https://stock-news.laohu8.com/highlight/detail?id=1194003246","media":"cnbc","summary":"KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains ","content":"<div>\n<p>KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden's top tax rate on capital gains, dividends would be among highest in developed world</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden's top tax rate on capital gains, dividends would be among highest in developed world\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"source_url":"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1194003246","content_text":"KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people would pay almost 49% total.\nOnly Ireland has a higher top rate – 51% on dividends.\nThere are many caveats. Perhaps most important, the highest U.S. rate applies to relatively few people, the top 0.3%. In other countries, the top rate applies across a broader pool of taxpayers.\n\nThe U.S. would tax capital gains and dividends for the rich at among the highest rates in the developed world if President Joe Biden's proposal were enacted.\nThe top rate high-earning Americans pay on dividends and the sale of appreciated assets would jump to nearly 49%, when combining all federal and state taxes, according to the Tax Foundation.\nTop tax rates on long-term capital gains for individuals in developed countries\nThe U.S. would have the highest top capital-gains tax rates among OECD countries if President Biden's proposal were enacted. The 48.6% rate includes a 3.8% net investment income tax and states' average top rate. It would apply to those with more than $1 million of income.\nNote: Data as of April 2021. Tax rates represent the top marginal capital-gains rates individuals paid for long-held shares. Include exemptions and surtaxes. Tax base and holding period vary between countries. U.S. rate includes state deductions for federal income taxes. Source: Tax Foundation, Bloomberg Tax, PwC\nIreland is the only other developed nation to levy a higher tax on investment income – 51% on dividends. But when it comes to capital gains, the U.S. would claim the highest top rate, according to Tax Foundationdata.\n(Unlike the U.S., many countries tax capital gains and dividends at different rates.)\n“If the [Biden] proposal went through, we’re right at the top of the world,” according to James Hines Jr., a law and economics professor at the University of Michigan and research director at its Office of Tax Policy Research.\nTop tax rates on dividends for individuals in developed countries\nThe U.S. would have one of the highest top dividend tax rates among OECD countries if President Biden's proposal were enacted. The 48.6% rate includes a 3.8% net investment income tax and states' average top rate. It would apply to those with more than $1 million of income.\nNote: Data as of April 2021. Tax rates represent the top marginal rate individuals paid on dividends. Include credits and surtaxes. U.S. rate includes state deductions for federal income taxes. *Japan rate for 2020. Current-year rate not available in the OECD dataset. Source: Tax Foundation, OECD\nThe U.S. currently taxes qualified dividends and long-term capital gains for the wealthiest citizens at about 29%. (Again, that’s a combined rate that includes state and federal taxes.)\nThat levy is about average among the 37 nations in the Organization for Economic Co-operation and Development, according to tax experts.\nThe top 0.3%\nOf course, there are many caveats to this analysis.\nIt’s difficult to compare tax burdens across countries due to extreme variation in certain details, according to experts.\nFor one, the top U.S. rate would apply to relatively few taxpayers each year. Other developed countries impose their top tax rate on a broader pool of people.\nThe Biden administration policy targets the richest Americans — the top 0.3% — because they are often able to manipulate the tax system in their favor, according to a White House official. It’s therefore unfair to compare the top tax rate more broadly, the official said.\nA recent ProPublicareportfound that some of the world’s wealthiest executives — like Warren Buffett, Jeff Bezos, Michael Bloomberg and Elon Musk —pay little to no taxes compared to their wealth.\nThe wealthiest taxpayers often receive income from so-called “capital income” like interest, dividends and capital gains.\nBiden’s proposal would raise the top federal rate on long-term capital gains and qualified dividends to 39.6%, from 20%, for taxpayers with annual income over $1 million.\n(Under current law, a 3.8%net investment income taxalso applies to taxpayers with more than $200,000 of income and married couples with more than $250,000. Most states also impose a separate tax on capital gains and dividends — the average top state rate is 5.2%,accordingto the Tax Foundation.)\nCombined, that yields a top rate of 48.6%.\nDenmark and Chile are the only other developed nations with a capital-gains tax rate of at least 40%. And relative to dividends, that’s true for just three countries: Ireland, Korea and Denmark.\nBiden’s proposal is part of a broader plan toraise taxes for households making more than $400,000 a year, to help fund domestic initiatives that largely benefit the low and middle class. The plan would change capital gains taxes in other ways, too, including taxing appreciated assets upon an owner’s death.\nProgressive tax system\nBut most Americans would pay a much lower federal tax rate than the headline top rate.\nIndeed, the U.S. capital-gains tax regime is progressive relative to other countries, according to Garrett Watson, a senior policy analyst at the Tax Foundation.\nSingle taxpayers with between roughly $40,000 and $446,000 of income pay 15% on their long-term capital gains or dividends in 2021. Those with less income don’t pay any taxes.\n\n The top bracket includes a lot of people in the U.K., whereas that wouldn’t be true in the U.S.James Hines Jr.RESEARCH DIRECTOR AT THE UNIVERSITY OF MICHIGAN’S OFFICE OF TAX POLICY RESEARCH\n\nBut France, for example, has a flat 30% tax rate on capital gains and dividends — meaning it applies to everyone regardless of income. (High earners pay an additional 4%.) The Netherlands, Israel, Germany, Japan and Hungary also impose a flat tax.\nEven in nations without a flat tax, their top rate may include a broader swath of the population.\n“The top bracket includes a lot of people in the U.K., whereas that wouldn’t be true in the U.S.,” Hines said.\nAlso, rules across developed countries may bump their tax rates up to levels higher than they might initially appear.\nFor example, nine OECD countries — Belgium, the Czech Republic, Korea, Luxembourg, New Zealand, Slovakia, Slovenia, Switzerland and Turkey — have a 0% tax on capital gains.\nBut they do tax dividends. And some levy a tax if the asset isn’t held for a certain length of time. In Slovenia, for example, the 0% tax only applies to assets held for at least 20 years. Rates could be as high as 27.5% for shorter holding periods.\nU.S. states\nPlus, U.S. states vary greatly in how they tax capital gains and dividends, according to Hines.\nFor example, residents of Alaska, Florida, Nevada, South Dakota, Tennessee, Texas, Washington state and Wyoming wouldn’t owe additional state tax on capital gains,accordingto the Tax Foundation.\nTheir top rate under Biden’s proposal would be 43.4% (which includes the 39.6% federal rate and the 3.8% net investment income tax). By comparison, California, New York, and New Jersey would have combined rates of more than 54% for the wealthiest residents.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120037055,"gmtCreate":1624287702577,"gmtModify":1703832603515,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120037055","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162424539,"gmtCreate":1624072348321,"gmtModify":1703828228811,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Shiok","listText":"Shiok","text":"Shiok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162424539","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":122334934,"gmtCreate":1624596846728,"gmtModify":1703841363133,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/122334934","repostId":"1136202921","repostType":4,"repost":{"id":"1136202921","pubTimestamp":1624591759,"share":"https://ttm.financial/m/news/1136202921?lang=&edition=fundamental","pubTime":"2021-06-25 11:29","market":"us","language":"en","title":"Why Apple's Stock Valuation Could Present Long-Term Buying Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1136202921","media":"Benzinga","summary":"Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan St","content":"<p><b>Apple Inc.</b>(NASDAQ:AAPL) shares have shown&nbsp;muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.</p>\n<p><b>The Apple Analyst:</b>Katy Huberty reiterated an Overweight rating on Apple with a $162 price target.</p>\n<p><b>The Apple Takeaways:</b>The incoming call volume on Apple shares is at a low amid investor concerns over a seasonally low&nbsp;period in the iPhone cycle,regulatory risk&nbsp;and difficult comps relative to the COVID-19-driven work-from-home&nbsp;and study-from-home&nbsp;demand, Huberty said in a note.</p>\n<p>Additionally, investors fear&nbsp;a more evolutionary iPhone s-cycle will lead to extended&nbsp;iPhone replacement cycles, the analyst said.</p>\n<p>Revenues will likely decline in 2022, increasing the likelihood of negative estimate revisions, she said.</p>\n<p>\"We recognize these risks but have a more positive outlook,\" Huberty said.</p>\n<p>The dominant bear case narrative now is the iPhone entering a more modest upgrade or \"s\" cycle —&nbsp;a period when iPhone revenue historically declined at a double-digit rate, the analyst said. She forecast a low risk of similar iPhone revenue decline next year.</p>\n<p>This is due to the longer period of iPhone replacement cycle relative to the past, an expansion to Apple's trade-in, financing and installment offers and 5G adoption, which is still in its nascent stage, Huberty said.</p>\n<p>\"Taken together, these factors build confidence that the iPhone 13 cycle will not look like past s-cycles, which is reflected in our updated FY22 iPhone forecast of 231M units,\" the analyst said.</p>\n<p>The June quarter&nbsp;will be stronger than originally expected, as iPhone and iPad builds are tracking ahead of Morgan Stanley's estimate, she said.</p>\n<p>Huberty&nbsp;raised her June quarter revenue and EPS estimates by 3%-5%.</p>\n<p>Apple's catalyst path is more back-end loaded this year, the analyst said.</p>\n<p>The company can drive low-teens annual revenue growth and high-teens annual EPS growth between fiscal years 2020 and 2023, she said.</p>\n<p>\"At24xFV/FCF, we believe the current valuation presents a good long-term buying opportunity.\"</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Apple's Stock Valuation Could Present Long-Term Buying Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Apple's Stock Valuation Could Present Long-Term Buying Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.\nThe Apple Analyst:Katy ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21707490/why-apples-stock-valuation-could-present-long-term-buying-opportunity","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136202921","content_text":"Apple Inc.(NASDAQ:AAPL) shares have shown muted performanceyear-to-date, and an analyst at Morgan Stanley sees long-term buying opportunity in the shares of the tech giant.\nThe Apple Analyst:Katy Huberty reiterated an Overweight rating on Apple with a $162 price target.\nThe Apple Takeaways:The incoming call volume on Apple shares is at a low amid investor concerns over a seasonally low period in the iPhone cycle,regulatory risk and difficult comps relative to the COVID-19-driven work-from-home and study-from-home demand, Huberty said in a note.\nAdditionally, investors fear a more evolutionary iPhone s-cycle will lead to extended iPhone replacement cycles, the analyst said.\nRevenues will likely decline in 2022, increasing the likelihood of negative estimate revisions, she said.\n\"We recognize these risks but have a more positive outlook,\" Huberty said.\nThe dominant bear case narrative now is the iPhone entering a more modest upgrade or \"s\" cycle — a period when iPhone revenue historically declined at a double-digit rate, the analyst said. She forecast a low risk of similar iPhone revenue decline next year.\nThis is due to the longer period of iPhone replacement cycle relative to the past, an expansion to Apple's trade-in, financing and installment offers and 5G adoption, which is still in its nascent stage, Huberty said.\n\"Taken together, these factors build confidence that the iPhone 13 cycle will not look like past s-cycles, which is reflected in our updated FY22 iPhone forecast of 231M units,\" the analyst said.\nThe June quarter will be stronger than originally expected, as iPhone and iPad builds are tracking ahead of Morgan Stanley's estimate, she said.\nHuberty raised her June quarter revenue and EPS estimates by 3%-5%.\nApple's catalyst path is more back-end loaded this year, the analyst said.\nThe company can drive low-teens annual revenue growth and high-teens annual EPS growth between fiscal years 2020 and 2023, she said.\n\"At24xFV/FCF, we believe the current valuation presents a good long-term buying opportunity.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151194802,"gmtCreate":1625066527106,"gmtModify":1703735400249,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/151194802","repostId":"2147169298","repostType":4,"repost":{"id":"2147169298","pubTimestamp":1625064508,"share":"https://ttm.financial/m/news/2147169298?lang=&edition=fundamental","pubTime":"2021-06-30 22:48","market":"us","language":"en","title":"Better Buy: Virgin Galactic vs. Lockheed Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2147169298","media":"Motley Fool","summary":"These two businesses are in the same industry but couldn't be more different.","content":"<p>The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"space race,\" launching test rockets and satellites for businesses and the U.S. government. But there are plenty of other companies in this private space race. One is <b>Virgin Galactic</b> (NYSE:SPCE), which was started by Richard Branson in 2004 and went public through a special purpose acquisition company (SPAC) in 2019. Another is <b>Lockheed Martin</b> (NYSE:LMT), the world's largest defense contractor.</p>\n<p>Which is a better buy: Virgin Galactic or Lockheed Martin? Let's take a look.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5f0851439294a2ef253f90479b7d5b2\" tg-width=\"700\" tg-height=\"491\"><span>Image source: Getty Images.</span></p>\n<h2>Virgin Galactic</h2>\n<p>Virgin Galactic is trying to build a modern aerospace company with a focus on consumer trips. Its goal is to develop \"a new generation of space vehicles to open space for everyone,\" according to its website. It has manufactured and will continue to manufacture different spaceships, with a goal of targeting researchers and wealthy private individuals for sub-orbital flights. Each ticket costs $250 thousand, and the company has a total of&nbsp; approximately 600 Future Astronauts (what it calls customers who have booked future flights) at the end of the first quarter.</p>\n<p>One thing investors should note with Virgin Galactic is that it doesn't actually have a business yet. In Q1 it brought in $0 of revenue (yes, that number is correct), burned $50 million, and has a little over $600 million in cash on its balance sheet. That cash pile gives it a good cushion, at least for a few quarters, but it is likely that the company will need to raise more money in the coming years.</p>\n<p>It has typically done that by issuing stock. Since going public in 2019, its shares outstanding have gone up 179%. Virgin Galactic currently has a market cap of $12.8 billion. Since it doesn't have a business right now, there's not much to reference this market cap to, but it implies that investors should expect the company to do at least a few billion in sales and hundreds of millions in profits at some point.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ab1895d73d79c678e757ad436915a12\" tg-width=\"720\" tg-height=\"433\"><span>Data by YCharts.</span></p>\n<h2>Lockheed Martin</h2>\n<p>Lockheed Martin is an American defense, aerospace, security, and technology company that has been doing business for the U.S. government for decades. Its largest business comes from aeronautics (which includes things like fighter jets), but it also has large missile, mission systems, and space-business lines as well. In fact, Lockheed Martin was the company that designed a helicopter for NASA that could fly on Mars.</p>\n<p>The conglomerate is guiding for around $68 billion in sales and $8.9 billion in cash generated from operations this year. With a market cap of $106 billion, the stock has a forward price-to-operating-cash-flow (P/OCF) of 11.9. Lockheed also returns tons of cash to shareholders through dividends and share repurchases. Its dividend yield is 2.72%, and its share count has come down each of the last five years.</p>\n<h2>So which is the better buy?</h2>\n<p>After comparing these two stocks, I think it is clear which is better to own: Lockheed Martin. Virgin Galactic does not have an actual business right now, is hemorrhaging cash, and has seen its share count go up 179% in less than two years. At this time, buying shares in Virgin Galactic is not investing but speculating.</p>\n<p>Lockheed Martin, on the other hand, has a diversified business and the most reliable customer in the world (the U.S. government). Plus, it consistently returns cash to shareholders through dividends and share repurchases. It might not have the hype of Virgin Galactic, whose shares seem to go up or down 10% a day, but Lockheed Martin is the better buy for long-term investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: Virgin Galactic vs. Lockheed Martin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: Virgin Galactic vs. Lockheed Martin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMT":"洛克希德马丁","SPCE":"维珍银河"},"source_url":"https://www.fool.com/investing/2021/06/30/better-buy-virgin-galactic-vs-lockheed-martin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147169298","content_text":"The aerospace, rocket launching, and defense industries seem to be on the verge of a huge expansion over the coming decades. Companies like SpaceX and Blue Origin have paved the way for this private \"space race,\" launching test rockets and satellites for businesses and the U.S. government. But there are plenty of other companies in this private space race. One is Virgin Galactic (NYSE:SPCE), which was started by Richard Branson in 2004 and went public through a special purpose acquisition company (SPAC) in 2019. Another is Lockheed Martin (NYSE:LMT), the world's largest defense contractor.\nWhich is a better buy: Virgin Galactic or Lockheed Martin? Let's take a look.\nImage source: Getty Images.\nVirgin Galactic\nVirgin Galactic is trying to build a modern aerospace company with a focus on consumer trips. Its goal is to develop \"a new generation of space vehicles to open space for everyone,\" according to its website. It has manufactured and will continue to manufacture different spaceships, with a goal of targeting researchers and wealthy private individuals for sub-orbital flights. Each ticket costs $250 thousand, and the company has a total of  approximately 600 Future Astronauts (what it calls customers who have booked future flights) at the end of the first quarter.\nOne thing investors should note with Virgin Galactic is that it doesn't actually have a business yet. In Q1 it brought in $0 of revenue (yes, that number is correct), burned $50 million, and has a little over $600 million in cash on its balance sheet. That cash pile gives it a good cushion, at least for a few quarters, but it is likely that the company will need to raise more money in the coming years.\nIt has typically done that by issuing stock. Since going public in 2019, its shares outstanding have gone up 179%. Virgin Galactic currently has a market cap of $12.8 billion. Since it doesn't have a business right now, there's not much to reference this market cap to, but it implies that investors should expect the company to do at least a few billion in sales and hundreds of millions in profits at some point.\nData by YCharts.\nLockheed Martin\nLockheed Martin is an American defense, aerospace, security, and technology company that has been doing business for the U.S. government for decades. Its largest business comes from aeronautics (which includes things like fighter jets), but it also has large missile, mission systems, and space-business lines as well. In fact, Lockheed Martin was the company that designed a helicopter for NASA that could fly on Mars.\nThe conglomerate is guiding for around $68 billion in sales and $8.9 billion in cash generated from operations this year. With a market cap of $106 billion, the stock has a forward price-to-operating-cash-flow (P/OCF) of 11.9. Lockheed also returns tons of cash to shareholders through dividends and share repurchases. Its dividend yield is 2.72%, and its share count has come down each of the last five years.\nSo which is the better buy?\nAfter comparing these two stocks, I think it is clear which is better to own: Lockheed Martin. Virgin Galactic does not have an actual business right now, is hemorrhaging cash, and has seen its share count go up 179% in less than two years. At this time, buying shares in Virgin Galactic is not investing but speculating.\nLockheed Martin, on the other hand, has a diversified business and the most reliable customer in the world (the U.S. government). Plus, it consistently returns cash to shareholders through dividends and share repurchases. It might not have the hype of Virgin Galactic, whose shares seem to go up or down 10% a day, but Lockheed Martin is the better buy for long-term investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120083660,"gmtCreate":1624288187950,"gmtModify":1703832621820,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/120083660","repostId":"1194003246","repostType":4,"repost":{"id":"1194003246","pubTimestamp":1624281440,"share":"https://ttm.financial/m/news/1194003246?lang=&edition=fundamental","pubTime":"2021-06-21 21:17","market":"us","language":"en","title":"Biden's top tax rate on capital gains, dividends would be among highest in developed world","url":"https://stock-news.laohu8.com/highlight/detail?id=1194003246","media":"cnbc","summary":"KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains ","content":"<div>\n<p>KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden's top tax rate on capital gains, dividends would be among highest in developed world</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden's top tax rate on capital gains, dividends would be among highest in developed world\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"source_url":"https://www.cnbc.com/2021/06/21/biden-tax-plan-raises-top-capital-gains-dividend-tax-rate-to-among-highest-in-world.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1194003246","content_text":"KEY POINTS\n\nPresident Joe Biden proposed a top federal tax rate of 39.6% on long-term capital gains and qualified dividends. With average state taxes and a 3.8% federal surtax, the wealthiest people would pay almost 49% total.\nOnly Ireland has a higher top rate – 51% on dividends.\nThere are many caveats. Perhaps most important, the highest U.S. rate applies to relatively few people, the top 0.3%. In other countries, the top rate applies across a broader pool of taxpayers.\n\nThe U.S. would tax capital gains and dividends for the rich at among the highest rates in the developed world if President Joe Biden's proposal were enacted.\nThe top rate high-earning Americans pay on dividends and the sale of appreciated assets would jump to nearly 49%, when combining all federal and state taxes, according to the Tax Foundation.\nTop tax rates on long-term capital gains for individuals in developed countries\nThe U.S. would have the highest top capital-gains tax rates among OECD countries if President Biden's proposal were enacted. The 48.6% rate includes a 3.8% net investment income tax and states' average top rate. It would apply to those with more than $1 million of income.\nNote: Data as of April 2021. Tax rates represent the top marginal capital-gains rates individuals paid for long-held shares. Include exemptions and surtaxes. Tax base and holding period vary between countries. U.S. rate includes state deductions for federal income taxes. Source: Tax Foundation, Bloomberg Tax, PwC\nIreland is the only other developed nation to levy a higher tax on investment income – 51% on dividends. But when it comes to capital gains, the U.S. would claim the highest top rate, according to Tax Foundationdata.\n(Unlike the U.S., many countries tax capital gains and dividends at different rates.)\n“If the [Biden] proposal went through, we’re right at the top of the world,” according to James Hines Jr., a law and economics professor at the University of Michigan and research director at its Office of Tax Policy Research.\nTop tax rates on dividends for individuals in developed countries\nThe U.S. would have one of the highest top dividend tax rates among OECD countries if President Biden's proposal were enacted. The 48.6% rate includes a 3.8% net investment income tax and states' average top rate. It would apply to those with more than $1 million of income.\nNote: Data as of April 2021. Tax rates represent the top marginal rate individuals paid on dividends. Include credits and surtaxes. U.S. rate includes state deductions for federal income taxes. *Japan rate for 2020. Current-year rate not available in the OECD dataset. Source: Tax Foundation, OECD\nThe U.S. currently taxes qualified dividends and long-term capital gains for the wealthiest citizens at about 29%. (Again, that’s a combined rate that includes state and federal taxes.)\nThat levy is about average among the 37 nations in the Organization for Economic Co-operation and Development, according to tax experts.\nThe top 0.3%\nOf course, there are many caveats to this analysis.\nIt’s difficult to compare tax burdens across countries due to extreme variation in certain details, according to experts.\nFor one, the top U.S. rate would apply to relatively few taxpayers each year. Other developed countries impose their top tax rate on a broader pool of people.\nThe Biden administration policy targets the richest Americans — the top 0.3% — because they are often able to manipulate the tax system in their favor, according to a White House official. It’s therefore unfair to compare the top tax rate more broadly, the official said.\nA recent ProPublicareportfound that some of the world’s wealthiest executives — like Warren Buffett, Jeff Bezos, Michael Bloomberg and Elon Musk —pay little to no taxes compared to their wealth.\nThe wealthiest taxpayers often receive income from so-called “capital income” like interest, dividends and capital gains.\nBiden’s proposal would raise the top federal rate on long-term capital gains and qualified dividends to 39.6%, from 20%, for taxpayers with annual income over $1 million.\n(Under current law, a 3.8%net investment income taxalso applies to taxpayers with more than $200,000 of income and married couples with more than $250,000. Most states also impose a separate tax on capital gains and dividends — the average top state rate is 5.2%,accordingto the Tax Foundation.)\nCombined, that yields a top rate of 48.6%.\nDenmark and Chile are the only other developed nations with a capital-gains tax rate of at least 40%. And relative to dividends, that’s true for just three countries: Ireland, Korea and Denmark.\nBiden’s proposal is part of a broader plan toraise taxes for households making more than $400,000 a year, to help fund domestic initiatives that largely benefit the low and middle class. The plan would change capital gains taxes in other ways, too, including taxing appreciated assets upon an owner’s death.\nProgressive tax system\nBut most Americans would pay a much lower federal tax rate than the headline top rate.\nIndeed, the U.S. capital-gains tax regime is progressive relative to other countries, according to Garrett Watson, a senior policy analyst at the Tax Foundation.\nSingle taxpayers with between roughly $40,000 and $446,000 of income pay 15% on their long-term capital gains or dividends in 2021. Those with less income don’t pay any taxes.\n\n The top bracket includes a lot of people in the U.K., whereas that wouldn’t be true in the U.S.James Hines Jr.RESEARCH DIRECTOR AT THE UNIVERSITY OF MICHIGAN’S OFFICE OF TAX POLICY RESEARCH\n\nBut France, for example, has a flat 30% tax rate on capital gains and dividends — meaning it applies to everyone regardless of income. (High earners pay an additional 4%.) The Netherlands, Israel, Germany, Japan and Hungary also impose a flat tax.\nEven in nations without a flat tax, their top rate may include a broader swath of the population.\n“The top bracket includes a lot of people in the U.K., whereas that wouldn’t be true in the U.S.,” Hines said.\nAlso, rules across developed countries may bump their tax rates up to levels higher than they might initially appear.\nFor example, nine OECD countries — Belgium, the Czech Republic, Korea, Luxembourg, New Zealand, Slovakia, Slovenia, Switzerland and Turkey — have a 0% tax on capital gains.\nBut they do tax dividends. And some levy a tax if the asset isn’t held for a certain length of time. In Slovenia, for example, the 0% tax only applies to assets held for at least 20 years. Rates could be as high as 27.5% for shorter holding periods.\nU.S. states\nPlus, U.S. states vary greatly in how they tax capital gains and dividends, according to Hines.\nFor example, residents of Alaska, Florida, Nevada, South Dakota, Tennessee, Texas, Washington state and Wyoming wouldn’t owe additional state tax on capital gains,accordingto the Tax Foundation.\nTheir top rate under Biden’s proposal would be 43.4% (which includes the 39.6% federal rate and the 3.8% net investment income tax). By comparison, California, New York, and New Jersey would have combined rates of more than 54% for the wealthiest residents.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151195446,"gmtCreate":1625066508485,"gmtModify":1703735399257,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Yumz","listText":"Yumz","text":"Yumz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151195446","repostId":"1168354842","repostType":4,"repost":{"id":"1168354842","pubTimestamp":1625064927,"share":"https://ttm.financial/m/news/1168354842?lang=&edition=fundamental","pubTime":"2021-06-30 22:55","market":"us","language":"en","title":"Amazon Is Still The Undisputed King Of Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=1168354842","media":"TheStreet","summary":"Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains t","content":"<p>Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.</p>\n<p>Last year was outstanding for cloud infrastructure, as the industry generated over $60 billion in revenues globally. At least this is what Gartner’s most recently issuedreportsuggests. IaaS sales grew a whopping 41% over 2019, driven by an acceleration in cloud adoption.</p>\n<p>One of the great beneficiaries of the cloud trends has been Amazon. The company, through its Amazon Web Services division, produced over 40% of the total industry revenues, reinforcing its status as the undisputed king of cloud infrastructure in the world.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a2c7a47d64871690408cff1b60106bca\" tg-width=\"1200\" tg-height=\"899\"><span>Figure 1: Amazon Web Serviced (AWS).</span></p>\n<p><b>A look at the numbers</b></p>\n<p>The table below summarizes Gartner’s findings about cloud IaaS. Amazon’s revenues, at $26.2 billion, were more than double Microsoft’s, the number two player in the space. All other competitors combined, Microsoft aside, produced less in IaaS revenues than Amazon.</p>\n<p>The worse news for Amazon is that its market share has declined noticeably since 2019. The company used to control nearly 45% of the industry but lost roughly four percentage points in 12 months. It looks like each of the next four competitors nibbled away at Amazon’s dominance in 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/65fc2aae6052c89cc17d34000360050d\" tg-width=\"825\" tg-height=\"513\"><span>Figure 2: Worldwide IaaS public market cloud services market share, 2019-2020.</span></p>\n<p>Worth noting, the table above addresses cloud infrastructure only, which I estimate to represent at least 60% of Amazon Web Services revenues. Not listed are cloud platform (PaaS) and packaged software (SaaS) – the latter of which Amazon is not a large player in.</p>\n<p><b>Why cloud matters</b></p>\n<p>Cloud adoption is one of those secular trends of the past decade – along with the internet in the 1990s, big data and connected devices in the 2000s – that has reached escape velocity. Gartner has offered the following quote that supports the idea:</p>\n<blockquote>\n “The era of CIOs investing in cloud IaaS and PaaS discretely is long over. Cloud market will continue to grow, [and] the real opportunity for providers comes from growth in cloud-adjacent technology markets such as edge, 5G and AI.”\n</blockquote>\n<p>For the revenue growth opportunities alone, cloud is an important factor in Amazon’s success. But what some may still not know is that AWS, representing only 12% of Amazon’s revenues in 2020, accounted for nearly 60% of the company’s operating profits. And probably even more so than e-commerce, Amazon’s cloud business is likely to see margins expand with gains of scale.</p>\n<p>Therefore, for as long as the table above continues to look good, the Seattle-based cloud giant will likely see profits and cash flow rise – and Amazon stock should benefit.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Is Still The Undisputed King Of Cloud</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Is Still The Undisputed King Of Cloud\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.\nLast year was...</p>\n\n<a href=\"https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/aws/amazon-is-still-the-undisputed-king-of-cloud","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168354842","content_text":"Accelerated cloud adoption has led to dizzying growth in IaaS revenues in 2020, and Amazon remains the number one player in the space. Here is why this matters to Amazon stock investors.\nLast year was outstanding for cloud infrastructure, as the industry generated over $60 billion in revenues globally. At least this is what Gartner’s most recently issuedreportsuggests. IaaS sales grew a whopping 41% over 2019, driven by an acceleration in cloud adoption.\nOne of the great beneficiaries of the cloud trends has been Amazon. The company, through its Amazon Web Services division, produced over 40% of the total industry revenues, reinforcing its status as the undisputed king of cloud infrastructure in the world.\nFigure 1: Amazon Web Serviced (AWS).\nA look at the numbers\nThe table below summarizes Gartner’s findings about cloud IaaS. Amazon’s revenues, at $26.2 billion, were more than double Microsoft’s, the number two player in the space. All other competitors combined, Microsoft aside, produced less in IaaS revenues than Amazon.\nThe worse news for Amazon is that its market share has declined noticeably since 2019. The company used to control nearly 45% of the industry but lost roughly four percentage points in 12 months. It looks like each of the next four competitors nibbled away at Amazon’s dominance in 2020.\nFigure 2: Worldwide IaaS public market cloud services market share, 2019-2020.\nWorth noting, the table above addresses cloud infrastructure only, which I estimate to represent at least 60% of Amazon Web Services revenues. Not listed are cloud platform (PaaS) and packaged software (SaaS) – the latter of which Amazon is not a large player in.\nWhy cloud matters\nCloud adoption is one of those secular trends of the past decade – along with the internet in the 1990s, big data and connected devices in the 2000s – that has reached escape velocity. Gartner has offered the following quote that supports the idea:\n\n “The era of CIOs investing in cloud IaaS and PaaS discretely is long over. Cloud market will continue to grow, [and] the real opportunity for providers comes from growth in cloud-adjacent technology markets such as edge, 5G and AI.”\n\nFor the revenue growth opportunities alone, cloud is an important factor in Amazon’s success. But what some may still not know is that AWS, representing only 12% of Amazon’s revenues in 2020, accounted for nearly 60% of the company’s operating profits. And probably even more so than e-commerce, Amazon’s cloud business is likely to see margins expand with gains of scale.\nTherefore, for as long as the table above continues to look good, the Seattle-based cloud giant will likely see profits and cash flow rise – and Amazon stock should benefit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150921896,"gmtCreate":1624883633715,"gmtModify":1703846939524,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/150921896","repostId":"2146339002","repostType":4,"repost":{"id":"2146339002","pubTimestamp":1624880751,"share":"https://ttm.financial/m/news/2146339002?lang=&edition=fundamental","pubTime":"2021-06-28 19:45","market":"us","language":"en","title":"How Facebook Is Quietly Preparing to Dominate Virtual Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2146339002","media":"Motley Fool","summary":"VR gaming accounts for less than 1% of the gaming market, but Facebook is going all in. What does Zuckerberg know that we don't?","content":"<p>According to The Verge, nearly 20% of <b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b>'s (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios for years, most recently BigBox VR (creator of <i>Population: One</i>, the <i>Fortnite</i> of VR) and Unit 2 Games (creator of Craya, a <b>Roblox</b>-esque VR gaming platform), for undisclosed sums.</p>\n<p>These continuous investments in talent and studio acquisitions may seem steep for a business segment that accounts for less than 3% of Facebook's top line. But Mark Zuckerberg's ambitious vision for VR is powering a shopping spree that likely won't stop anytime soon. Is Facebook ahead of the game, or will its Oculus VR venture fail to move the needle?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f686cdff7303434853836ea6ee34a8f6\" tg-width=\"700\" tg-height=\"438\"><span>Image source: Getty Images.</span></p>\n<h2>The future of VR gaming</h2>\n<p>Zuckerberg has been talking up VR more than usual lately, partly thanks to accelerated adoption of the Oculus Quest 2 VR headset (according to Facebook -- but the company does not explicitly report figures for sold VR hardware). The CEO's first major talking point in Facebook's latest earnings report was VR and AR, predicting \"augmented and virtual reality to unlock a massive amount of value, both in people's lives and the economy overall.\"</p>\n<p>His excitement about the technology is not unwarranted -- Fortune Business Insights forecasts that the global market for VR gaming will reach $45.2 billion by 2027 (from $5.1 billion in 2019). This translates to a compounded annual growth rate (CAGR) of 31.8%, compared to a CAGR of only 5.3% for the overall gaming console market over the same forecast period.</p>\n<h2>How Facebook got ahead</h2>\n<p>Facebook's strategy for VR gaming domination starts with laying a solid foundation of technology and developer talent. In classic Facebook fashion, its primary tactic has been acquiring existing VR hardware and software companies.</p>\n<p>Since acquiring Oculus VR for $2 billion in 2014, the company has made significant progress in improving its VR hardware to better suit customers' needs. The current Oculus Quest 2 is a stand-alone headset (i.e., no wires to trip on or tangle up while playing) and requires no external device (such as a console or PC). Conversely, <b>Sony</b>'s (NYSE:SONY) wired PlayStation VR headset requires a PlayStation console. The Quest 2's wireless, low-hardware conveniences combined with its lower price point relative to any other major headset on the market give Facebook a competitive edge when it comes to hardware.</p>\n<p>But even the best VR headset is useless without great games, making Facebook's VR studio acquisitions crucial to building up its VR ecosystem. By acquiring small yet high-performing studios, Facebook is securing revenue from already-popular VR games on Oculus and retaining top software developers to create exclusive content within the Oculus platform. Considering the company's standard four-year stock option vesting schedule, it's unlikely that developers from studios like BigBox or Unit 2 will jump ship to work for a competitor anytime soon.</p>\n<h2>Why it'll stay ahead</h2>\n<p>If you know Facebook's business model, you're probably wondering when ads come into play. The company has announced that it will begin testing ads in select games on the Oculus platform, but it's still up in the air what exactly the ad experience will look like once testing begins -- and how VR gamers will react.</p>\n<p>If the company can manage to integrate ads without breaking the immersive gaming experience, it will help developers earn more revenue (thus, attracting more developers to the Oculus platform) and could even make games more realistic. For example, real ads appearing on in-game TV screens and billboards would not break players' immersion in their gaming world, while still driving revenue for developers and Facebook.</p>\n<p>Beyond attracting developers for top-tier content, Facebook has a unique edge in attracting consumers as well -- its massive social networking user base. No other VR headset can offer such easy accessibility (low price point with no required console purchase) and such a high potential for network effects.</p>\n<p>For example, it would be much easier for a friend to influence you to purchase a $300 all-in-<a href=\"https://laohu8.com/S/AONE\">one</a> VR headset than a PlayStation console <i>and</i> headset, which would total more than twice the cost of the Quest 2. Don't get me wrong -- Sony is a leading competitor in the VR gaming space and has shipped the most VR hardware units to date, but the company's network effects are arguably limited to existing PlayStation owners (about 15.7 million monthly active users, between the PS4 and the PS5).</p>\n<p>Facebook's 2.8 billion monthly active users have much more potential to add value to the Oculus platform by sheer volume of players, especially when it comes to popular social VR games like <i>Population: One</i>, <i>Craya</i>, and <i>Beat Saber Multiplayer</i> (developed by yet another Facebook-acquired studio, Beat Games). Social gaming experiences are inherently more valuable with more players.</p>\n<p>While some VR multiplayer games are cross-platform (i.e., an Oculus player can game with a PS VR player), Facebook will likely tighten up its exclusive content offerings to attract and retain players. As long as the company rolls out ad content in a way that feels relatively organic to Oculus players, Facebook is set up for success in rapidly gaining market share in VR gaming.</p>\n<h2>What to watch for</h2>\n<p>While Facebook's VR gaming revenue isn't reported explicitly (yet), the company's \"other revenue\" business segment is primarily Oculus. In Facebook's first-quarter 2021 earnings report, this segment grew 146% year over year to $732 million, implying an impressive growth rate for the company's VR business. Further, the Quest 2 has become the most used VR headset on popular gaming platform Steam, and by many estimates the Quest 2 is selling at least twice as fast as PlayStation VR, despite lagging behind in current overall market share.</p>\n<p>Keep an eye on this \"other revenue\" segment in future earnings reports, as well as any hard figures reported by the company on VR gaming revenue. More cautious investors may also want to wait for Facebook to complete its in-game ad testing process before investing based on the company's growth potential in VR. It is undoubtedly a risk to user growth if ad content is not executed smoothly.</p>\n<p>It's impossible to dive into every point in Facebook's value and growth story in <a href=\"https://laohu8.com/S/AONE.U\">one</a> sitting, but the stock seems fairly valued given its growth potential -- FB is even rated \"undervalued\" by Morningstar. The company's wide economic moat in social gaming is unmatched thanks to a massive user base and vast user data, and these competitive advantages can easily translate to driving profits and market share for its VR gaming business.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Facebook Is Quietly Preparing to Dominate Virtual Reality</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Facebook Is Quietly Preparing to Dominate Virtual Reality\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-28 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to The Verge, nearly 20% of Facebook's (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/27/how-facebook-is-quietly-preparing-to-dominate-virt/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146339002","content_text":"According to The Verge, nearly 20% of Facebook's (NASDAQ:FB) employees are working exclusively on virtual reality (VR) and augmented reality (AR). Plus, the company has been acquiring small VR studios for years, most recently BigBox VR (creator of Population: One, the Fortnite of VR) and Unit 2 Games (creator of Craya, a Roblox-esque VR gaming platform), for undisclosed sums.\nThese continuous investments in talent and studio acquisitions may seem steep for a business segment that accounts for less than 3% of Facebook's top line. But Mark Zuckerberg's ambitious vision for VR is powering a shopping spree that likely won't stop anytime soon. Is Facebook ahead of the game, or will its Oculus VR venture fail to move the needle?\nImage source: Getty Images.\nThe future of VR gaming\nZuckerberg has been talking up VR more than usual lately, partly thanks to accelerated adoption of the Oculus Quest 2 VR headset (according to Facebook -- but the company does not explicitly report figures for sold VR hardware). The CEO's first major talking point in Facebook's latest earnings report was VR and AR, predicting \"augmented and virtual reality to unlock a massive amount of value, both in people's lives and the economy overall.\"\nHis excitement about the technology is not unwarranted -- Fortune Business Insights forecasts that the global market for VR gaming will reach $45.2 billion by 2027 (from $5.1 billion in 2019). This translates to a compounded annual growth rate (CAGR) of 31.8%, compared to a CAGR of only 5.3% for the overall gaming console market over the same forecast period.\nHow Facebook got ahead\nFacebook's strategy for VR gaming domination starts with laying a solid foundation of technology and developer talent. In classic Facebook fashion, its primary tactic has been acquiring existing VR hardware and software companies.\nSince acquiring Oculus VR for $2 billion in 2014, the company has made significant progress in improving its VR hardware to better suit customers' needs. The current Oculus Quest 2 is a stand-alone headset (i.e., no wires to trip on or tangle up while playing) and requires no external device (such as a console or PC). Conversely, Sony's (NYSE:SONY) wired PlayStation VR headset requires a PlayStation console. The Quest 2's wireless, low-hardware conveniences combined with its lower price point relative to any other major headset on the market give Facebook a competitive edge when it comes to hardware.\nBut even the best VR headset is useless without great games, making Facebook's VR studio acquisitions crucial to building up its VR ecosystem. By acquiring small yet high-performing studios, Facebook is securing revenue from already-popular VR games on Oculus and retaining top software developers to create exclusive content within the Oculus platform. Considering the company's standard four-year stock option vesting schedule, it's unlikely that developers from studios like BigBox or Unit 2 will jump ship to work for a competitor anytime soon.\nWhy it'll stay ahead\nIf you know Facebook's business model, you're probably wondering when ads come into play. The company has announced that it will begin testing ads in select games on the Oculus platform, but it's still up in the air what exactly the ad experience will look like once testing begins -- and how VR gamers will react.\nIf the company can manage to integrate ads without breaking the immersive gaming experience, it will help developers earn more revenue (thus, attracting more developers to the Oculus platform) and could even make games more realistic. For example, real ads appearing on in-game TV screens and billboards would not break players' immersion in their gaming world, while still driving revenue for developers and Facebook.\nBeyond attracting developers for top-tier content, Facebook has a unique edge in attracting consumers as well -- its massive social networking user base. No other VR headset can offer such easy accessibility (low price point with no required console purchase) and such a high potential for network effects.\nFor example, it would be much easier for a friend to influence you to purchase a $300 all-in-one VR headset than a PlayStation console and headset, which would total more than twice the cost of the Quest 2. Don't get me wrong -- Sony is a leading competitor in the VR gaming space and has shipped the most VR hardware units to date, but the company's network effects are arguably limited to existing PlayStation owners (about 15.7 million monthly active users, between the PS4 and the PS5).\nFacebook's 2.8 billion monthly active users have much more potential to add value to the Oculus platform by sheer volume of players, especially when it comes to popular social VR games like Population: One, Craya, and Beat Saber Multiplayer (developed by yet another Facebook-acquired studio, Beat Games). Social gaming experiences are inherently more valuable with more players.\nWhile some VR multiplayer games are cross-platform (i.e., an Oculus player can game with a PS VR player), Facebook will likely tighten up its exclusive content offerings to attract and retain players. As long as the company rolls out ad content in a way that feels relatively organic to Oculus players, Facebook is set up for success in rapidly gaining market share in VR gaming.\nWhat to watch for\nWhile Facebook's VR gaming revenue isn't reported explicitly (yet), the company's \"other revenue\" business segment is primarily Oculus. In Facebook's first-quarter 2021 earnings report, this segment grew 146% year over year to $732 million, implying an impressive growth rate for the company's VR business. Further, the Quest 2 has become the most used VR headset on popular gaming platform Steam, and by many estimates the Quest 2 is selling at least twice as fast as PlayStation VR, despite lagging behind in current overall market share.\nKeep an eye on this \"other revenue\" segment in future earnings reports, as well as any hard figures reported by the company on VR gaming revenue. More cautious investors may also want to wait for Facebook to complete its in-game ad testing process before investing based on the company's growth potential in VR. It is undoubtedly a risk to user growth if ad content is not executed smoothly.\nIt's impossible to dive into every point in Facebook's value and growth story in one sitting, but the stock seems fairly valued given its growth potential -- FB is even rated \"undervalued\" by Morningstar. The company's wide economic moat in social gaming is unmatched thanks to a massive user base and vast user data, and these competitive advantages can easily translate to driving profits and market share for its VR gaming business.","news_type":1},"isVote":1,"tweetType":1,"viewCount":408,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120037055,"gmtCreate":1624287702577,"gmtModify":1703832603515,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120037055","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162424539,"gmtCreate":1624072348321,"gmtModify":1703828228811,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Shiok","listText":"Shiok","text":"Shiok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162424539","repostId":"2144779308","repostType":4,"repost":{"id":"2144779308","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624022423,"share":"https://ttm.financial/m/news/2144779308?lang=&edition=fundamental","pubTime":"2021-06-18 21:20","market":"us","language":"en","title":"New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End","url":"https://stock-news.laohu8.com/highlight/detail?id=2144779308","media":"Investors","summary":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange.","content":"<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 21:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Atai Life Sciences</b>, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.</p>\n<p>The Germany-based company, backed by billionaire investor and <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.</p>\n<p>The Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.</p>\n<p>Last week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.</p>\n<p>Credit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.</p>\n<h2>Psychedelic Drug Stocks</h2>\n<p>The Atai IPO follows that of <b>Compass Pathways</b>, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.</p>\n<p><b>MindMed</b>, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.</p>\n<p>MindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.</p>\n<p>More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.</p>\n<p>Sales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.</p>\n<p>Spravato, a drug from&nbsp;<b>Johnson &amp; Johnson</b> that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.</p>\n<h2>Atai IPO Details, Planned Trials</h2>\n<p>Atai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.</p>\n<p>In that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.</p>\n<p>Atai invests in companies developing mental health treatments, often with a majority interest or an option to get <a href=\"https://laohu8.com/S/AONE\">one</a>. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.</p>\n<p>One of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.</p>\n<p>However, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.</p>\n<p>Atai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.</p>\n<p>These Are The 5 Best Stocks To Buy And Watch Now</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATAI":"ATAI Life Sciences B.V.*"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144779308","content_text":"Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, making it the latest such company to hit a major exchange as it tries to bring hallucinogens to the world of therapeutics.\nThe Germany-based company, backed by billionaire investor and PayPal co-founder Peter Thiel, priced its IPO at $15, compared compared to an expected range of $13 and $15.\nThe Atai IPO will generate gross proceeds of $225 million from the sale of 15 million shares. Underwriters also have an option to buy another 2.25 million shares.\nLast week, Atai said it planned to offer 14,286,000 shares in its IPO. The offering also included a 30-day option for the underwriters to buy up to 2,142,900 additional shares.\nCredit Suisse, Citigroup, Cowen, and Berenberg were book-running managers for the offering. Other book-running managers included Cantor, RBC Capital Markets and Canaccord Genuity, a big dealmaker in the cannabis industry that has shown up in psychedelics as well.\nPsychedelic Drug Stocks\nThe Atai IPO follows that of Compass Pathways, which is researching a therapy regimen that uses a crystalline form of psilocybin. Atai is also a large shareholder in Compass.\nMindMed, another psychedelics developer, listed on the Nasdaq in April. Others trade in Canada.\nMindMed rose 0.3% in premarket trading on the stock market today. Compass Pathways was quiet.\nMore psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges. But investing in the space carries the same challenges as other nascent drug developers, where trials can burn through money and still come up short of approval.\nSales, let alone profits, could be years away. Regulators, such as the FDA and DEA, can approve research on drugs, even though some, like LSD and psilocybin, are considered controlled substances. But executives in the industry have said regulatory approval, rather than state or local legalization, will define growth in the psychedelics industry.\nSpravato, a drug from Johnson & Johnson that uses a derivative of ketamine, was approved in 2019 for treatment-resistant depression.\nAtai IPO Details, Planned Trials\nAtai was founded in 2018 by Christian Angermayer, a biotech investor. Angermayer also founded Apeiron Investment Group, which is Atai's biggest shareholder, according to the Atai IPO prospectus.\nIn that filing, from April, Atai said it had raised $362.3 million as of that time. Atai reported a net loss last year of around $179 million.\nAtai invests in companies developing mental health treatments, often with a majority interest or an option to get one. It oversees 10 therapeutic programs handled by such companies. Five of those involve some form of psychedelic compound, such as MDMA — also known as ecstasy or molly — ibogaine, R-ketamine and DMT, a substance found in ayahuasca.\nOne of those companies, Atai said, Recognify Life Sciences, has initiated a Phase 2a trial in the United States. Atai said it expected to start a Phase 2 trial for another program this year, with three more next year.\nHowever, drug development is expensive and time-consuming. If funding falls through, those efforts could be derailed. Atai said it had cash of $97.2 million as of the end of last year.\nAtai also said that under its agreements with Recognify and DemeRx — another company it has invested in that is researching ibogaine — they could lose their majority interest in both companies if Atai misses certain milestone payments.\nThese Are The 5 Best Stocks To Buy And Watch Now","news_type":1},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123888429,"gmtCreate":1624415778261,"gmtModify":1703836005089,"author":{"id":"3580457839820972","authorId":"3580457839820972","name":"JasSeah","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580457839820972","authorIdStr":"3580457839820972"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123888429","repostId":"2145061761","repostType":4,"repost":{"id":"2145061761","pubTimestamp":1624411200,"share":"https://ttm.financial/m/news/2145061761?lang=&edition=fundamental","pubTime":"2021-06-23 09:20","market":"us","language":"en","title":"Second Sight Medical Products Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145061761","media":"Business Wire","summary":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Se","content":"<p><b>LOS ANGELES, June 23, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/EYES\">Second Sight Medical Products</a>, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.</p>\n<p>The offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.</p>\n<p>ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.</p>\n<p>The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.</p>\n<p>The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About the Orion Visual Cortical Prosthesis System</b></p>\n<p>Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.</p>\n<p><b>About Second Sight Medical Products, Inc.</b></p>\n<p>Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Second Sight Medical Products Announces Pricing of Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSecond Sight Medical Products Announces Pricing of Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/second-sight-medical-products-announces-005900674.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145061761","content_text":"LOS ANGELES, June 23, 2021--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (\"Second Sight\" or the \"Company\"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, solely to cover over-allotments. All of the shares of common stock are being offered by the Company.\nThe offering is expected to close on June 25, 2021, subject to satisfaction of customary closing conditions.\nThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.\nThe Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.\nThe securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-256904), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the \"SEC\") on June 8, 2021 and declared effective on June 14, 2021. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout the Orion Visual Cortical Prosthesis System\nLeveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\nAbout Second Sight Medical Products, Inc.\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at https://secondsight.com/.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}